Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide and semaglutide represent two distinct approaches to GLP-1 receptor activation, with tirzepatide offering dual-pathway stimulation of both GLP-1 and GIP receptors. Clinical trials show tirzepatide produces approximately 20–22% body weight reduction at maximum dose, compared to semaglutide's 15–17% reduction. PlexusDx offers both compounded options at affordable flat-rate pricing, with genetic testing available to personalize your choice.

How Tirzepatide and Semaglutide Work Differently

Semaglutide is a single-action GLP-1 receptor agonist, meaning it binds to one hormone pathway that controls appetite, blood sugar, and gastric emptying. Tirzepatide is a dual agonist that activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, engaging two separate metabolic pathways simultaneously. This fundamental difference in mechanism explains why tirzepatide studies consistently show larger weight reductions in comparable patient populations.

The GLP-1 pathway has been well-studied for over a decade, with proven effects on satiety and food intake. The GIP pathway was less understood until recently, but 2023 and 2024 clinical data show it enhances energy expenditure, improves insulin sensitivity, and may offer additional metabolic benefits beyond appetite suppression. PlexusDx offers both single and dual-pathway options to match your individual response profile.

Weight Loss Results: What the Clinical Evidence Shows

In the STEP trials, semaglutide-treated patients lost an average of 15% body weight at the highest dose over 68 weeks, with some individuals achieving 17–18% reductions. The SURMOUNT trials, which studied tirzepatide, reported mean weight losses of 20–22% at maximum dose over comparable timeframes. These differences are clinically meaningful: a 200-pound person losing 15% versus 22% represents a difference of 14 pounds in total weight reduction.

Individual response varies significantly based on genetics, lifestyle, baseline metabolism, and adherence. Some patients on semaglutide achieve excellent results exceeding 20% loss, while others may plateau at lower reductions. The Precision Peptide Genetic Test offered by PlexusDx maps GLP-1R and GIPR genetic variants that predict pathway sensitivity, helping explain why one medication may outperform another for a specific individual. Age, starting weight, and concurrent lifestyle changes also influence outcomes independent of medication type.

Sustainable Weight Loss: Maintenance and Rebound Prevention

Both semaglutide and tirzepatide require ongoing use to maintain weight loss—stopping either medication typically results in gradual weight regain over months. However, tirzepatide's dual-pathway approach may support more durable metabolic changes because it addresses energy expenditure and insulin sensitivity in addition to appetite control. Early evidence suggests tirzepatide patients maintain weight loss somewhat better during dose reduction or pause periods, though long-term head-to-head maintenance studies remain limited.

True sustainable weight loss combines medication with habit formation, dietary consistency, and regular physical activity. Compounded tirzepatide from PlexusDx starts at $249 per month at a flat rate, meaning your dose can increase without your price increasing. This pricing structure removes cost barriers to optimal dosing, which correlates with better long-term adherence and weight maintenance. Combining either medication with behavioral strategies and nutritional coaching creates the strongest foundation for sustained results.

Choosing Between Tirzepatide and Semaglutide: Personalization Matters

The choice between tirzepatide and semaglutide depends on your genetic predispositions, prior medication responses, metabolic profile, and treatment goals. Patients with strong baseline insulin resistance or prediabetic glucose patterns may respond more dramatically to tirzepatide's dual GLP-1/GIP activation. Those with primarily appetite-driven weight gain and normal insulin sensitivity may achieve excellent results with semaglutide monotherapy at lower cost and simplicity.

PlexusDx offers Compounded Tirzepatide Injection starting at $249 per month and Compounded Semaglutide Injection starting at $149 per month, with no membership fees, insurance required, or flat per-compound pricing increases. The Precision Peptide Genetic Test ($99 add-on after your first month) sequences 14 metabolic pathways and 49 peptides, including GLP1R and GIPR variants, to predict your individual response profile. This genetic data informs whether dual-pathway tirzepatide or single-pathway semaglutide offers your best sustainability window.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Will tirzepatide always produce more weight loss than semaglutide?

No—individual response varies based on genetics, lifestyle, and baseline health status. While tirzepatide shows higher average weight loss in clinical trials (20–22% vs. 15–17%), some semaglutide patients achieve excellent results exceeding 20% reduction. The Precision Peptide Genetic Test helps predict which pathway you'll respond to most strongly.

What evidence supports tirzepatide for sustainable weight loss?

The SURMOUNT trials tracked tirzepatide patients for up to 104 weeks and showed sustained weight loss maintenance with continued dosing. Tirzepatide's dual GLP-1/GIP mechanism improves insulin sensitivity and energy expenditure, mechanisms linked to more durable metabolic changes compared to single GLP-1 activation alone. Both medications require ongoing use to prevent weight regain.

How much does tirzepatide cost with PlexusDx, and can I afford dose increases?

PlexusDx Compounded Tirzepatide Injection starts at $249 per month flat, with no flat per-compound pricing increases. Your dose may need to go up. Your price won't. All PlexusDx medications are HSA/FSA-eligible, and the service is available in all 50 states without insurance requirements.

Are there safety differences between tirzepatide and semaglutide?

Both medications carry similar side effects: nausea, vomiting, constipation, and rare pancreatitis risk. Tirzepatide may cause slightly more gastrointestinal effects due to dual-pathway activation, but serious adverse events are uncommon in either medication. All PlexusDx compounds are sourced from licensed 503A compounding pharmacies and require medical supervision.

How does the Precision Peptide Genetic Test help me choose between tirzepatide and semaglutide?

The test sequences variants in GLP1R and GIPR genes (plus 47 other peptide-pathway genes) that predict receptor sensitivity and metabolic response. Patients with genetic markers favoring GIP pathway activation may achieve greater tirzepatide benefit, while GLP-1R-dominant profiles may respond optimally to semaglutide. This $99 test (after your first month) personalizes your medication selection.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves